UNLIMITED TURBO LONG - GILEAD SCIENCES | Real-time Bid/Ask 02:55:03 2024-06-05 EDT | ||
| 1.1 EUR / 1.13 EUR | +2.29% |
|
| Current month | -0.91% | ||
| 1 month | -8.40% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-06-05 | 1.1 | +0.92% |
| 24-06-04 | 1.09 | +4.81% |
| 24-06-03 | 1.04 | -5.45% |
| 24-05-31 | 1.1 | 0.00% |
| 24-05-30 | 1.1 | +2.80% |
Delayed Quote Börse Stuttgart
Last update June 05, 2024 at 02:53 am
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | 
BNP Paribas
|
| WKN | PP8UT1 |
| ISIN | DE000PP8UT14 |
| Date issued | 2018-05-22 |
| Strike | 53.05 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.77 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.88 € |
|---|---|
| Lowest since issue | 0.7 € |
| Spread | 0.03 € |
| Spread % | 2.65% |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
64.16
USD
Average target price
82.7
USD
Spread / Average Target
+28.89%
- Stock Market
- Certificates
- Certificat
